Renalytix AI Plc (GB:RENX) has released an update.
Renalytix AI Plc, a leader in kidney health diagnostics, will unveil its third-quarter fiscal year 2024 financial results on May 15, before the U.S. market opens. A conference call and live webcast will follow the announcement to discuss the company’s financial performance, strategic initiatives, and progress in partnerships and regulatory matters. Renalytix is renowned for its pioneering bioprognosis™ technology and KidneyIntelX test, which aids in the risk assessment of kidney function decline.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
